| [1] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
| [2] |
YU Yong, MA Shouliang, SHENG Yuqin.
Allergic Reactions and Treatment Involving Sodium Dimercaptopropane Sulfate Injection during Copper Chelation for Wilson’s Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 771-775.
|
| [3] |
YANG Shengxi, XU Juntong, TU Wenlian.
Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.
|
| [4] |
GUO Yijun, CHEN Xia, MENG Ping.
Adverse drug reaction reports in 141 cases of orally administered targeted anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1137-1142.
|
| [5] |
WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo.
Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
|
| [6] |
HUANG Huanjun, MAI Jiaheng, ZHANG Yunhui, GUO Chenchen, LIANG Weiting.
Adverse drug reaction induced by antineoplastic drugs in a cancer hospital: an analysis of 613 cases
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 324-328.
|
| [7] |
LIU Yadi, WANG Xue, YIN Xiaoyang, LIU Zeyu, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian.
Clinical applicability and safety risks of puerarin in tumor adjuvant therapy based on CiteSpace and bioinformatics technology
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1407-1414.
|
| [8] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
| [9] |
LUO Shishu, QU Jie, ZHOU Nan, XU Cuixiang, LIU Yi, ZHANG Lijie, WANG Jianhua.
289 cases of adverse drug reactions associated with monoclonal antibody antitumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 444-448.
|
| [10] |
DONG Baihui, JANG Hong, XIAO Xiang, FU Dongliang, LI Chunyan.
Echocardiographic monitoring during medication with trastuzumab following treatment of breast cancer patients with anthracyclines
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 557-560.
|
| [11] |
WANG Peixu, XU Lingxiao, LIU Shuhua.
Determination of clindamycin in drainage fluid of bone marrow infection by HPLC
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 69-71.
|
| [12] |
XU Baoyu, SHEN Hua, LI Xin, HAN Feng.
Efficacy of chemotherapy combined with anlotinib against advanced pancreatic cancer
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 72-73.
|
| [13] |
WANG Jingliu, LIU Pingyu, LI Xin, HAN Feng.
Rationality of Prices of Antineoplastic Drugs Based on Price Comparison Analysis
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1162-1165.
|
| [14] |
ZHANG Xiumin, CAI Jing.
Pharmaceutical Care of Aggravating Renal Function Injury in an Elderly Patient with Lung Cancer Undergoing Chemotherapy
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 491-495.
|
| [15] |
LI Zhenzong, LI Dan, WANG Hongyun, GONG Lei, GAO Hua, LIU Qian.
Effects of Fulvestrant Inducing Apoptosis of Pituitary Adenoma Cells and the Acute Toxicity Study
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 325-328.
|
